Other
Resistance
0
Pipeline Programs↗
18
Active Trials↗
10
Companies Involved↗
Resistance is an early-stage landscape with 0 programs across 10 companies. The most active players are GSK, AbbVie, Gilead.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
111
clinical trials
Completed66 · 59%
Unknown status16 · 14%
Recruiting9 · 8%
Terminated6 · 5%
Not yet recruiting5 · 5%
Active, not recruiting4 · 4%
Other5 · 5%
Clinical Trials
Trial Activity
111 trials
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
Recruiting·—·N/A·NCT04288427·120 enrolled
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT05950139·12 enrolled
Resistance Training and Injection Treatment for Achilles Enthesopathy
Active, not recruiting·—·N/A·NCT04232358·50 enrolled
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
Active, not recruiting·—·Phase 2·NCT03085719·18 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)